Evidence for the efficacy of peginterferon alfa-2a (40 KD) (pegasys) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors

被引：5

作者：

Cooksley, WGE

Piratvisuth, T

Wang, YJ

Mahachai, V

Chao, YC

Tanwandee, T

Chutaputti, A

Chang, WY

Zahm, FE

Pluck, N

机构：

[1] Royal Brisbane Hosp, Dept Clin Res, Brisbane, Qld 4029, Australia

[2] Songklanakarin Hosp, Dept Med, Songkhla, Thailand

[3] Chulalongkorn Hosp, Dept Med, Bangkok, Thailand

[4] Siriraj Hosp, Dept Med, Bangkok, Thailand

[5] Pramongkutklao Hosp, Dept Med, Bangkok, Thailand

[6] Vet Gen Hosp, Taipei, Taiwan

[7] Tri Serv Gen Hosp, Taipei, Taiwan

[8] Kaohsiung Univ Hosp, Kaohsiung, Taiwan

[9] Hoffmann La Roche Ag, Clin Dev, CH-4002 Basel, Switzerland

[10] Roche Prod Ltd, Clin Dev, Welwyn Garden City AL7 3AY, Herts, England

来源：

关键词：

D O I：

10.1016/S0168-8278(02)80017-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：8 / 8

页数：1